Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and preliminary effectiveness of TQB2930 combined with chemotherapy, with or without bevacizumab, in people who have HER2-abnormally expressed, locally advanced or metastatic colorectal cancer that cannot be removed by surgery. This phase IbII clinical trial aims to better understand how these treatments work together to target cancer cells expressing the HER2 protein. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and includes adult participants from 18 to 75 years old. Participants are randomly assigned to receive either TQB2930 injection plus chemotherapy and bevacizumab injection or TQB2930 injection plus chemotherapy alone. Chemotherapy drugs include oxaliplatin and capecitabine tablets or irinotecan hydrochloride injection with capecitabine tablets. TQB2930 targets HER2 proteins on tumor cells to reduce their growth, while bevacizumab works by blocking blood vessel formation that feeds tumors. Treatment continues until disease progression or other criteria are met. Throughout the study, participants undergo assessments such as measuring tumor response, monitoring adverse events, and collecting blood samples to analyze drug levels and immune responses. The main outcomes include determining the recommended dose for phase 2, safety monitoring from consent until 28 days after the last dose, and tracking objective response rates for up to 24 months. Secondary outcomes include survival rates, duration of response, and drug behavior in the body. Participants are monitored regularly during treatment and follow-up periods lasting up to two years.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the agreement between four different test methods and a reference assay for MET overexpression in patients with untreated non-small cell lung cancer NSCLC. The study focuses on treatment-nave patients with unresectable locally advanced, metastatic, or recurrent NSCLC. It is a multicenter, prospective study sponsored by AstraZeneca, aiming to improve understanding of tumor gene profiling and MET concordance. Participants undergo next-generation sequencing NGS testing initially to determine their EGFR mutation status. Based on these results, participants are assigned to one of three cohorts those with specific EGFR mutations, those without actionable genomic alterations, and those with other actionable genomic alterations. Additional diagnostic tests such as MET IHC testing, PD-L1, and Her2 testing are performed for participants in the first cohort. During the study, participants provide tissue samples collected after diagnosis but before any antitumor treatment. The research team analyzes various biomarkers and treatment patterns up to 90 days after the last patient in. Participants are monitored through these tests and gene profiling to assess the concordance of different diagnostic methods. The total participation duration aligns with the study completion date in March 2027.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.
Actively Recruiting
Researchers are evaluating the safety of inhaled TQC3721 suspension, a Phosphodiesterase34 inhibitor, in patients with moderate to severe Chronic Obstructive Pulmonary Disease COPD. This phase 3 study aims to observe adverse effects and lung function changes, providing valuable information about the treatment in this patient group. Participants receive TQC3721 suspension via inhalation at a dose of 6mg2ml twice daily. Two groups are studied one group uses the suspension for 24 weeks, and the other for 12 weeks. The study includes an extended observation period for safety in the longer treatment group. During the trial, participants undergo lung function tests measuring the forced expiratory volume in 1 second FEV1, and lab tests to monitor for adverse events and abnormalities. The study tracks COPD exacerbations and other health changes for up to 48 weeks. Participants are monitored regularly to assess treatment safety and lung function over time.
Actively Recruiting
Researchers are conducting a prospective, multicenter, open-label, randomized controlled trial to compare two treatment strategies for adults with acute myocardial infarction AMI who have mild coronary artery narrowing. The study aims to determine if standard medical therapy alone is not worse than using drug-eluting stent DES implantation combined with standard therapy. This trial will include 2,000 patients with ST-segment elevation myocardial infarction STEMI or non-ST-segment elevation myocardial infarction NSTEMI from multiple centers in China. Participants will be randomly assigned to one of two groups one receiving guideline-recommended standard medical therapy alone, which includes dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other related medications and the other receiving DES implantation plus the same standard medical therapy. The study also includes a functional substudy with 120 participants assessing coronary microvascular dysfunction using pressure wire tests. The enrollment period is planned for 36 months, with a follow-up of at least 12 months after randomization and continued monitoring until study completion. During the study, participants will undergo coronary angiography and assessments of vessel function. Researchers will monitor for target lesion failure TLF, defined as cardiovascular death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization, over a median follow-up of 30 months. Additional outcomes include all-cause death, stroke, rehospitalization for heart conditions, and quality of life measures. The study tracks these outcomes through regular follow-up visits to evaluate the safety and effectiveness of the treatment approaches.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of oral paclitaxel solution combined with fruquintinib as a second-line treatment for adults with advanced or metastatic gastric or gastroesophageal junction cancer. This open-label, randomized trial compares this combination to chemotherapy selected by the investigator. The study aims to provide new options for patients whose cancer has progressed after first-line therapy. Participants receive either oral paclitaxel solution plus fruquintinib or investigator-chosen chemotherapy. The oral paclitaxel is given in 28-day cycles on days 1, 8, and 15, while fruquintinib is taken daily for 3 weeks followed by a week off. The comparator group receives injectable chemotherapy agents per clinical guidelines. Treatment continues until disease progression, unacceptable side effects, withdrawal, or study completion. During the study, participants undergo regular assessments including tumor measurements, survival status, and quality of life questionnaires. Safety is monitored from the first dose through 30 days after the last dose. Researchers measure progression-free survival as the primary outcome within 1 year and track overall survival up to 3 years. The total participation duration depends on treatment response and study timelines.
Actively Recruiting
Researchers are evaluating RC1416, a bispecific homodimer nanobody, in adults with severe uncontrolled asthma to assess its effectiveness and safety. This phase II study involves 195 participants diagnosed with moderate to severe asthma, aiming to improve lung function and reduce asthma symptoms according to the 2024 GINA guidelines. Participants will be randomly assigned to receive either RC1416 or a placebo by subcutaneous injection. Two different doses of RC1416 will be tested. The study will last 32 weeks, during which participants will be monitored regularly for treatment effects and safety. Throughout the study, participants will undergo lung function tests such as pre-bronchodilator forced expiratory volume in 1 second FEV1, peak expiratory flow, and forced vital capacity measurements. They will also complete questionnaires about asthma control and quality of life. Researchers will track asthma exacerbations, medication use, and adverse events. Blood samples will be collected for pharmacokinetics, pharmacodynamics, and anti-drug antibody analysis, ensuring comprehensive safety and efficacy monitoring for up to 32 weeks.
1-10 of 12
1